Mouse C9 Terminal Complement Complex Monoclonal Antibody | anti-C9 antibody

C9 Terminal Complement Complex (TCC, MAC complex) (FITC)

Cat. Num. AAA6008002

• Reactivity: Equine, Human, Porcine
• Applications: ELISA, Immunohistochemistry, Flow Cytometry, Functional Assay, Immunofluorescence
• Purity: Affinity Purified; Purified by Protein G affinity chromatography.
• Synonyms: C9 Terminal Complement Complex; Monoclonal Antibody; C9 Terminal Complement Complex (TCC; MAC complex) (FITC); Anti -C9 Terminal Complement Complex (TCC; anti-C9 antibody

• Host: Mouse
• Reactivity: Equine, Human, Porcine
• Clonality: Monoclonal
• Isotype: IgG2a
• Clone Number: 13A37
• Specificity: Recognizes a C9 neoantigen of the human TCC. Species Crossreactivity: equine and porcine.
• Purity/Purification: Affinity Purified; Purified by Protein G affinity chromatography.
• Form/Format: Supplied as a liquid in PBS, 0.1% BSA, 0.02% sodium azide. Labeled with fluorescein isothiocyanate (FITC).

• Applicable Applications for anti-C9 antibody: ELISA (EL/EIA), Immunohistochemistry (IHC), Flow Cytometry (FC/FACS), Immunofluorescence (IF)
• Application Notes: Suitable for use in Flow Cytometry, ELISA, Functional Studies, Immunofluorescence and Immunohistochemistry.; Dilution: Immunohistochemistry: Frozen; Immunohistochemistry: Paraffin; Flow Cytometry: 1:50
• Immunogen: Purified MAC
• Positive Control: Mucosa from patients with H. Pylori.
• Preparation and Storage: May be stored at 4 degree C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20 degree C. Aliquots are stable for 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. FITC conjugates are sensitive to light.

Related Product Information for anti-C9 antibody

The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.

Product Categories/Family for anti-C9 antibody

Antibodies; Abs to Complement

NCBI and Uniprot Product Information

• NCBI GI #: 4502511
• NCBI GeneID: 735
• NCBI Accession #: NP_001728.1
• NCBI GenBank Nucleotide #: NM_001737.3
• UniProt Accession #: P02748
• Molecular Weight: 63,173 Da
• NCBI Official Full Name: complement component C9
• NCBI Official Synonym Full Names: complement component 9
• NCBI Official Symbol: C9
• NCBI Protein Information: complement component C9
• UniProt Protein Name: Complement component C9
• Protein Family: Complement component
• UniProt Gene Name: C9
• UniProt Entry Name: CO9_HUMAN

NCBI Description

This gene encodes the final component of the complement system. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on bacterial membranes to form a pore, permitting disruption of bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009]

Uniprot Description

C9: Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC. Defects in C9 are a cause of complement component 9 deficiency (C9D). A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Belongs to the complement C6/C7/C8/C9 family.

Protein type: Membrane protein, integral; Extracellular matrix; Membrane protein, multi-pass; Apoptosis

Chromosomal Location of Human Ortholog: 5p14-p12

Cellular Component: membrane attack complex; integral to plasma membrane; cytoplasm; extracellular region; plasma membrane

Biological Process: complement activation, alternative pathway; regulation of complement activation; innate immune response; hemolysis by symbiont of host red blood cells; complement activation, classical pathway

Disease: Macular Degeneration, Age-related, 15; Complement Component 9 Deficiency